Shuttle Pharmaceuticals Holdings (SHPH) Gains from Investment Securities (2021 - 2022)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Gains from Investment Securities of $492700.0 for Q4 2022, up 34.64% year-over-year from $365926.0 in Q4 2021, and up 536.8% quarter-over-quarter from -$112797.0 in Q3 2022.
Shuttle Pharmaceuticals Holdings (SHPH) Gains from Investment Securities (2021 - 2022) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $492700.0 for Q4 2022.
- In Q4 2022, Gains from Investment Securities rose 34.64% year-over-year to $492700.0; the TTM figure through Dec 2022 stood at $772514.0 (changed N/A YoY), while the FY2023 annual figure was $1.3 million, up 223.21% from the prior year.
- Gains from Investment Securities for Q4 2022 stood at $492700.0, up from -$112797.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $492700.0 in Q4 2022, with the low at -$112797.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.87 Mn | 1.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 492,700.00 |
| Dec 31, 2022 | 492,700.00 |
| Sep 30, 2022 | -112,797.00 |
| Sep 30, 2022 | -112,797.00 |
| Dec 31, 2021 | 365,926.00 |
| Dec 31, 2021 | 365,926.00 |
| Sep 30, 2021 | 26,685.00 |
| Sep 30, 2021 | 26,685.00 |